GLPG0974: Completed Phase IIa enrollment

Galapagos completed enrollment of about 45 patients with mild to moderate UC in a double-blind, placebo-controlled, European Phase IIa trial evaluating 200 mg oral GLPG0974 twice daily for 4 weeks. ...